Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRS-342
- Development stage
- Unknown
- Lead developer
- Boston Pharmaceuticals
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
PRS-342 is a bispecific antibody fusion protein designed for immuno-oncology applications. It consists of an anti-GPC3 antagonistic antibody linked to a 4-1BB (CD137) agonistic Anticalin protein. The drug binds with high affinity to cells expressing both human GPC3 and 4-1BB, targeting GPC3-positive tumor cells and activating 4-1BB on tumor-infiltrating immune cells. This dual mechanism aims to provide potent costimulatory signals that enhance T-cell mediated cytotoxicity specifically within the tumor microenvironment, leading to increased T-cell infiltration and tumor cell killing. PRS-342 was originally developed by Pieris Pharmaceuticals using their proprietary Anticalin technology platform and has been licensed exclusively worldwide to Boston Pharmaceuticals for further development[1][2][3][5][7].
- Other names
- BOS 342BOS342BOS-342PRS 342PRS342PRS-342
02
Targets
TNFRSF9 (CD137 extracellular domain)GPC3 (Glypican-3)
Beyond the preview
Go deeper on PRS-342.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRS-342.